Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukemia

H Enright1, P B McGlave

  • 1Division of Hematology, University of Minnesota, Minneapolis 55455, USA.

Current Opinion in Hematology
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis B screening in hematology patients receiving intravenous immunoglobulin.

Transfusion·2024
Same author

Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices.

Thrombosis update·2024
Same author

Incidence of cutaneous T-cell lymphoma in the Republic of Ireland between 1994 and 2019.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Controlled placement of multiple CNS cell populations to create complex neuronal cultures.

PloS one·2017
Same author

Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis.

Annals of hematology·2014

Chronic myelogenous leukemia (CML) is a blood cancer caused by a specific genetic mutation. Treatments include interferon and stem cell transplants for better survival rates.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myelogenous leukemia (CML) is a hematopoietic malignancy.
  • CML is characterized by a Philadelphia chromosome, a translocation between chromosomes 9 and 22.
  • This translocation produces the BCR/ABL fusion protein, which has increased tyrosine kinase activity.

Purpose of the Study:

  • To describe the molecular basis of Chronic myelogenous leukemia (CML).
  • To outline conventional therapies and alternative treatment options for CML.
  • To discuss the prognostic significance of cytogenetic response to interferon therapy.

Main Methods:

  • Review of existing literature on CML pathogenesis and treatment.
  • Analysis of outcomes for conventional therapies (hydroxyurea, busulfan, interferon).

Related Experiment Videos

  • Evaluation of stem cell transplantation (related donor, unrelated donor, autologous) as a therapeutic option.

    • Main Results:

    • The BCR/ABL fusion protein drives CML development.
    • Interferon therapy can improve survival, particularly with cytogenetic response.
    • Early treatment with related donor marrow transplantation offers long-term survival in over 65% of patients.

    Conclusions:

    • Understanding the molecular mechanisms of CML is crucial for developing targeted therapies.
    • Stem cell transplantation is a highly effective treatment for CML, especially when performed early.
    • Alternative transplantation options exist for patients lacking a matched sibling donor.